Oncology
Metastatic Renal Cell Cancer
0
Pipeline Programs↗
3
Active Trials↗
8
Companies Involved↗
Metastatic Renal Cell Cancer is an early-stage landscape with 0 programs across 8 companies. The most active players are Pfizer, Roche, Novartis.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
30
clinical trials
Completed23 · 77%
Terminated4 · 13%
Active, not recruiting1 · 3%
Recruiting1 · 3%
Not yet recruiting1 · 3%
Clinical Trials
Trial Activity
30 trials
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
Recruiting·—·Phase 1·NCT07128680·33 enrolled
RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
Not yet recruiting·—·Phase 2·NCT07218692·35 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)